Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01050764
Other study ID # IRB-15919
Secondary ID BMT204SU-0331200
Status Terminated
Phase Phase 1/Phase 2
First received
Last updated
Start date June 2009
Est. completion date June 2014

Study information

Verified date June 2018
Source Stanford University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Patients with hematologic malignancies will receive myeloablative chemotherapy followed by stem cell rescue with bone marrow or hematopoietic peripheral blood stem cells collected by apheresis from a filgrastim- (G-CSF)-mobilized haploidentical related-donor, ie, hematopoietic peripheral blood stem cell transplant (HSCT).


Description:

This is dose-escalation study intended to evaluate the use of classification determinant 15-positive (CD15+), CD4+, CD127dim, and FoxP3+ regulatory T-cells (T-reg cells) supplemented by conventional T-cells (T-con cells), to enhance the efficacy of allogeneic (CliniMACS CD34+ selected) hematopoietic stem cell transplantation (allo-HSCT), in the setting of leukemia, lymphoma, and myelodysplastic syndrome (MDS). This study investigates amelioration of the impaired immune recovery and address the significant relapse incidence in the haploidentical HSCT setting.

Pre-transplant myeloablative conditioning will be melphalan; thiotepa; fludarabine and rabbit antithymocyte globulin (rATG).

Stem cell rescue will be with CD34+ selected cells. The rescue infusion will be supplemented with infusions of regulatory T-cells (T-reg) and conventional T-cells (T-con) from the same donor collection, on Treatment Days 14 and 16 respectively. CD34+ cell infusion day is Treatment Day 0.

T-reg cells are those cells enriched by immunomagnetic selection of CD25+ cells, and further purified by flow cytometric cell sorting for the CD15+, CD4+, CD127dim, FoxP3+ cell population. These cells are an enriched but naturally-occurring T-cell population.

T-con cells are unseparated/unfractionated cells, ie, as collected by the peripheral blood stem cells apheresis procedure.

Post-transplant follow-up is for 5 years.


Recruitment information / eligibility

Status Terminated
Enrollment 10
Est. completion date June 2014
Est. primary completion date August 2012
Accepts healthy volunteers No
Gender All
Age group N/A to 60 Years
Eligibility Inclusion Criteria

RECIPIENT

- Histopathologically-confirmed:

- Acute leukemia (in first remission with poor risk factors and molecular prognosis)

- Acute myelogenous leukemia (AML) with -5,-7, t (6;9), tri8, -11

- Acute lymphoblastic leukemia (ALL) with Ph+ t (9;22), t (4;22), (q34;q11)

- Acute leukemia with refractory disease or > Complete Remission (CR) 1

- Chronic myelogenous leukemia (CML) (accelerated, blast or second chronic phase)

- Myelodysplastic syndrome (in high and high intermediate risk categories)

- Non-Hodgkin's lymphoma (NHL) with poor risk features and not suitable for autologous transplantation

- Refractory Chronic lymphocytic leukemia (CLL)

- At least 21 days from the end of most recent prior therapy to start of the transplant conditioning regimen

- Must be < 60 years old at time of registration.

- Karnofsky Performance Status (KPS) > 70%

Must have related donor who is:

- Genotypically human leukocyte antigen (HLA) -A, B,C and DR beta 1 (DRB1), DQ loci haploidentical to the recipient (but differing for 2 to 3 HLA alleles on the unshared haplotype in the graft-versus-host disease (GvHD) direction)

- No HLA-matched sibling or matched-unrelated donor is identified.

- Adequate cardiac and pulmonary function (left ventricular ejection fraction (LVEF) > 45%, diffusing capacity of the lungs for carbon monoxide (DLCO) >50% corrected for hemoglobin)

- Serum creatinine < 1.5 mg/dL OR Creatinine clearance > 50 mL/min for those above serum creatinine at least 1.5 mg/dL

- Serum bilirubin < 2.0 mg/dL

- Alanine transaminase (ALT) < 2x upper normal limit (ULN) (unless secondary to disease)

- No prior myeloablative therapy or hematopoietic cell transplantation

DONOR:

- Age = 70 years

- Weight = 25 kg.

- Medical history and physical examination confirm good health status as defined by institutional standards

- Seronegative for HIV Ag within 30 days of apheresis collection for:

- Hepatitis B surface antigen (sAg) or polymerase chain reaction (PCR) +

- Hepatitis C ab or PCR+

- Genotypically haploidentical as determined by HLA typing

- Female donors (child-bearing potential) must have a negative serum or urine beta-human chorionic gonadotropin (HCG) test within 3 weeks of mobilization

- Capable of undergoing leukapheresis

- Has adequate venous access

- Willing to undergo insertion of a central catheter if leukapheresis via peripheral vein is inadequate

- Capable of agreeing to second donation of peripheral blood progenitor cell (PBPC) (or a bone marrow harvest) should the patient fail to demonstrate sustained engraftment following the transplant

- Institutional review board (IRB)-approved consent form signed by donor or legal guardian > 18 years of age

Donor Selection in the priority order:

- Recipient's biological mother preferred, if available

- Other available haploidentical donors will be selected based upon the presence of natural killer (NK) alloreactivity between donor and recipient by high-resolution HLA typing of the C locus. An NK-alloreactive donor will be preferentially chosen. Recipients lacking a killer immunoglobulin-like receptor (KIR)-ligand present in the donor along with the corresponding KIR defines "NK alloreactivity".

- If more than one NK-alloreactive donor is available, preference is to cytomegalovirus (CMV)-seronegative donor

Exclusion Criteria

RECIPIENT:

- Suitable candidate for autologous transplantation or allogeneic transplantation with an available matched-related or matched-unrelated donor

- Seropositive for:

- HIV ab

- Hepatitis B sAg or PCR+

- Hepatitis C ab or PCR+

- History of invasive Aspergillosis

- Any active, uncontrolled bacterial, viral or fungal infection

- Uncontrolled central nervous system (CNS) disease involvement

- Lactating female

DONOR:

- Evidence of active infection or viral hepatitis

- Factors of increased risk for complications from leukapheresis or granulocyte-colony stimulating factor (G-CSF) therapy

- Lactating female

- HIV-positive

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Regulatory T-cells
To ameliorate the impaired immune recovery and address the significant relapse incidence in the haploidentical setting. Cells will be selected by a tandem selection process and infused on day +14. These are the enriched but naturally-occurring regulatory T cells. Possible dose cohorts and levels are: Cohort 1 T-reg: 1 x 10e5/kg T-con: 3 x10e5/kg Cohort 2 T-reg: 3 x 10e5/kg T-con: 1 x 10e6/kg Cohort 3 T-reg: 1 x 10e6/kg T-con: 3 x 10e6/kg Cohort 4 T-reg: 3 x 10e6/kg T-con: 1 x 10e7/kg
Conventional T-cells
These are conventional (unselected) donor T-cells. Cell dosage of the infusion will be based on the CD3+ cell content and infused on day +16.
Melphalan
Anti-cancer chemotherapy drug administered IV at 140 mg/m² on Day -8 prior to HSCT (a component of the conditioning regiment prior to infusion of cells)
Thiotepa
Anti-cancer chemotherapy drug administered IV at 10 mg/kg on Day -7 prior to HSCT (a component of the conditioning regiment prior to infusion of cells)
Device:
Fludarabine
Anti-cancer chemotherapy drug administered IV at 160mg/m² on Days -6; -5; -4; and -3 prior to HSCT (a component of the conditioning regiment prior to infusion of cells
Drug:
Anti-thymocyte globulin, rabbit
Rabbit-derived antibodies against human T-cells used as transplant rejection prophylaxis. Administered at 6 mg/kg IV on Days -6; -5; -4; and -3 prior to HSCT
CliniMACS CD34 Reagent System
An in vitro medical device system that uses antibodies conjugated to magnetic beads to select and enrich for CD34+ blood stem cells from the allogeneic donor apheresis product prior to HSCT, while removing other cells that can cause GvHD. CD34+ cell dosage will be based on the participant's body weight.

Locations

Country Name City State
United States Stanford University School of Medicine Stanford California

Sponsors (2)

Lead Sponsor Collaborator
Everett Meyer Doris Duke Charitable Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum-tolerated Dose (MTD) of Regulatory and Conventional T-cells The maximum-tolerated dose (MTD) was to be determined based on the safety and feasibility observed for a pre-determined set of cellular dose level combinations of regulatory T-cells (T-reg) and conventional T-cells (T-con). 30 days after HSCT infusion
Secondary Acute Graft-versus-Host-Disease (aGvHD) The primary outcome was incidence of grade 3 or 4 acute graft-vs-host-disease (aGvHD), reported as the number of participants developing grade 3 or 4 aGvHD. 1 year
Secondary Overall Survival (OS), 1 Year Assessed as subjects remaining alive 12 months after CD34+ cell infusion (ie, excludes death due to any cause) 1 year
Secondary Median Overall Survival (OS) Reported as the median overall survival (OS) in months from infusion of the hematopoietic stem cells (HSCT) 25 months
Secondary To Measure the Incidence and Severity of Acute and Chronic GvHD Population of participants that received HSCT and T-reg plus T-con, and developed actue, chronic, or any graft vs host disease (GvHD) 1 year
Secondary Serious Infections Serious infections are reported as the number of participants experienced serious infections. 1 year
See also
  Status Clinical Trial Phase
Completed NCT02626715 - Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS Phase 2
Recruiting NCT02905552 - Myelodysplasic Syndromes and Risk Factors for Infection N/A
Completed NCT01772953 - Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT Phase 2
Suspended NCT01211691 - Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF) Phase 1/Phase 2
Active, not recruiting NCT06294275 - A Study of Single and Multiple Dose Administration of LP-001 in Healthy Subjects Phase 1
Completed NCT00533416 - Safety of ON 01910.Na in Patients With Myelodysplasia Phase 1
Active, not recruiting NCT04401748 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome Phase 3
Recruiting NCT04608110 - A Phase 1 Trial of ASTX030 in Patients With Myelodysplastic Syndrome Phase 1
Recruiting NCT03613532 - Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN Phase 1
Withdrawn NCT03486353 - A Study of FF-10501-01 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome Phase 2
Terminated NCT02259348 - Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation Phase 2
Terminated NCT01422486 - Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic Syndrome Phase 2
Terminated NCT01459159 - Study of (Telintra®) in Non-Del(5q) Myelodysplastic Syndrome Phase 2
Terminated NCT00542828 - Rabbit Anti-thymocyte Globulin in the Treatment of Patients With Low to Intermediate-1 Risk Myelodysplastic Syndrome Phase 2
Completed NCT01685619 - AML-MDS Novel Prognostic Tests Clinical Study
Recruiting NCT01861093 - Safety Study of Cord Blood Units for Stem Cell Transplants Phase 2
Unknown status NCT01983761 - Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation Phase 1/Phase 2
Recruiting NCT01758042 - Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders N/A
Completed NCT01221857 - Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies Phase 1/Phase 2
Completed NCT01338337 - Study of Vidaza (Azacitidine) Versus Support Treatment in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) Without the 5q Deletion and Transfusion Dependent Anaemia Phase 2